The OBRI is excited to share our latest publications:
- Discontinuation of tofacitinib and TNF inhibitors in patients with rheumatoid arthritis: analysis of pooled data from two registries in Canada. Supplementary material.
- Late-onset rheumatoid arthritis has a similar time to remission as younger-onset rheumatoid arthritis: results from the Ontario Best Practices Research Initiative.
- Disease activity trajectories for early and established rheumatoid arthritis: Real-world data from a rheumatoid arthritis cohort.
- Medical cannabis use by rheumatology patients in routine clinical care: results from The Ontario Best Practices Research Initiative.
- Differential influence of Clinical Disease Activity Index components based on disease state in rheumatoid arthritis patients: real-world results from the Ontario Best Practices Research Initiative.
- Physician- and Patient-reported Effectiveness Are Similar for Tofacitinib and TNFi in Rheumatoid Arthritis: Data From a Rheumatoid Arthritis Registry. Supplementary tables available here.
- Heterogeneity in Patient Characteristics and Differences in Treatment Across 4 Canadian Rheumatoid Arthritis Cohorts.
- Cardiovascular risk factors are negatively associated with rheumatoid arthritis disease outcomes.
- Changes in Market Share of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Results from the Ontario Best-Practice Research Initiative Database. Frailty and risk of osteoporotic fractures in patients with rheumatoid arthritis: Data from the Ontario Biologics Research Initiative.
- Impact of Concomitant Use of Disease Modifying Anti-Rheumatic Drugs and Methotrexate Administration Route on Durability of Biologic Treatment in Rheumatoid Arthritis: Results from The Ontario Best Practices Research Initiative (OBRI).